Background and Purpose: Endoscopic bariatric and metabolic therapies are minimally invasive alternatives that bridge the gap between pharmacological treatment and bariatric surgery. A novel duodenal metallic bypass sleeve (DMBS) was developed to induc...
Background and Purpose: Endoscopic bariatric and metabolic therapies are minimally invasive alternatives that bridge the gap between pharmacological treatment and bariatric surgery. A novel duodenal metallic bypass sleeve (DMBS) was developed to induce nutrient malabsorption while preserving ampullary patency and modulating incretin hormones. This study aimed to evaluate the technical feasibility, safety, and efficacy of the DMBS to suppress weight gain in a porcine model. Materials and Methods: The DMBS consisted of a disk-part, a sleeve-part, and four connecting wires. The characteristics of the DMBS were analyzed. Twelve pigs were randomly assigned to the control, DMBS@4wks, rebounding, and DMBS@8wks groups (n = 3 per group). The efficacy and safety of the DMBS were assessed by comparing the results of weight changes, follow-up radiological and endoscopic, hematologic, and histological examination. Results: DMBS placement and removal were technically successful in all study groups. The mean percentage of total body weight gain (%TBWG) in the DMBS-treated groups were significantly lower than that in the control group (all p < 0.05). The mean %TBWGs at 8 weeks were 51%, 46%, and 29% in the control, rebounding, and DMBS@8wks groups, respectively. DMBS-induced tissue hyperplasia and mucosal injury markers were significantly increased. In the DMBS-treated groups, increased glucose transporter type 1 (GLUT1) and glucagon-like peptide-1 (GLP-1) and decreased glucose-dependent insulinotropic peptide (GIP) levels were observed. Conclusion: The DMBS was technically feasible, effective, and safe in suppressing weight in the porcine model. This device seems to be a novel, minimally invasive endoscopic bariatric therapeutic option for obesity management. (Key words: Nutrient absorption, Glucose-dependent insulinotropic peptide, Glucagon-like peptide-1, Stent, Obesity)